Last Price
18.08
Today's Change
-0.35 (1.89%)
Day's Change
17.97 - 18.74
Trading Volume
6,696,245
Market Cap
20 Billion
Shares Outstanding
1 Billion
Avg Volume
8,961,169
Avg Price (50 Days)
17.32
Avg Price (200 Days)
14.23
PE Ratio
-46.36
EPS
-0.39
Earnings Announcement
06-Nov-2024
Previous Close
18.43
Open
18.51
Day's Range
17.97 - 18.74
Year Range
8.06 - 19.08
Trading Volume
6,201,843
1 Day Change
-1.90%
5 Day Change
-2.95%
1 Month Change
7.68%
3 Month Change
7.49%
6 Month Change
31.87%
Ytd Change
69.45%
1 Year Change
93.37%
3 Year Change
91.32%
5 Year Change
143.01%
10 Year Change
-65.61%
Max Change
1895.03%
No result.
Sector: Healthcare - Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Description:
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.